Inicio › Leucemia linfocítica crónica › Georgia
Ensayos clínicos de Leucemia linfocítica crónica en Georgia
16 estudios sobre Leucemia linfocítica crónica buscan participantes en Georgia.
Ciudades en Georgia
Texto oficial del estudio (inglés)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- y 4 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT05334069A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Emory University Winship Cancer Institute, Atlanta
- Northside Cancer Center, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06846671Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Central Georgia Cancer Care, Macon
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT07516093A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 jul 2026 · NCT07020533Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT06588478Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Atlanta Cancer Center, Newnan
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
ReclutandoFase 2Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 10 mar 2026 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- The Emory Clinic, Atlanta
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- The Emory Clinic, Atlanta
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Winship Cancer Institute of Emory University /ID# 230643, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT04895436Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Winship Cancer Institute at Emory University, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ene 2026 · NCT06043674De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.